KMB at a glance
Kimberly-Clark (KMB, SEC CIK 55785) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Kimberly-Clark (KMB) reported revenue of $16.4 billion (down 18.0% from FY2024) and net income of $2.0 billion. Diluted EPS was $6.07.
- As of September 30, 2026, 51 institutional investment managers tracked by SignalX reported holding Kimberly-Clark (KMB) shares worth $14.7 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $16.4B
- −18.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 51 funds
- $14.7B · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: global manufacturing and marketing of personal care, family care, and professional products with leading brands in 175+ countries
- New strategic focus: 2024 Transformation Initiative emphasizing proprietary innovation, margin optimization, and organizational agility for growth
- Major corporate transactions: agreement to acquire Kenvue, Inc. for $6.7 billion plus 280 million shares; formed joint venture divesting 51% of International Family Care and Professional segment for $1.7 billion
- Employee base steady at ~36,000 with 35% in North America and half in manufacturing/distribution roles
- Sustainability commitment: execution of climate goals approved by SBTi, targeting reduced fossil fuel plastics, forest fiber use, and greenhouse gas emissions with $150 million environmental compliance spend expected in 2026
Risk Factors
- Regulatory risk from tightening data privacy and cybersecurity laws worldwide, increasing compliance costs and potential liabilities related to breaches of consumer data
- Geopolitical exposure in Russia and surrounding region due to war in Ukraine, with operation curtailed and assets at risk of impairment
- Supply chain vulnerability from sole-source commodity suppliers and third-party manufacturers, risking production delays and cost increases
- Competitive pressure from private label manufacturers with lower production costs and e-commerce distribution intensifying market share threat
- Financial risk of credit rating downgrade increasing borrowing costs and reducing access to commercial paper market for funding
Management Discussion & Analysis
- Net sales $16.45B, down 2.1% YoY; organic sales up 1.7% driven by 2.5% volume growth, offset by divestitures and currency impacts
- Gross margin 36.0% vs 37.4%, down 140 bps; operating profit $2.35B, down 12.9%; adjusted operating profit $2.73B, flat YoY
- North America segment: sales $10.75B (-2.4%), operating profit $2.55B (+0.4%); International Personal Care sales $5.69B (-0.9%), operating profit $796M (-3.6%)
- Operating cash flow $2.8B, down from $3.2B; ongoing capital allocation includes $1.7B expected from IFP joint venture sale, transformation initiative costs approx. $1.5B pre-tax
- Management focused on 2024 Transformation Initiative to achieve $3B gross productivity savings by 2026; risks include birth rate declines, competitive pressures, input cost volatility, geopolitical uncertainties including Russia and Ukraine conflict impacts
AI summary of the KMB 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Kenvue Acquisition integration: complex system consolidation could disrupt demand fulfillment and financial reporting
- OTC product safety: oral phenylephrine removal could require reformulation or withdrawal of Sudafed PE and Tylenol Cold & Flu
- Regulatory compliance: expanded OTC operations require cGMP compliance across company and third-party manufacturing facilities
- Supply continuity: transition away from J&J manufacturing could increase defects, quality issues, and delivery costs
- Indemnification exposure: talc claims outside the United States and Canada remain Kenvue’s responsibility with unquantifiable liability
Management Discussion & Analysis
- Q3 revenue $4,134M, down 0.4% YoY from $4,150M; organic sales declined 1.3%
- Gross margin 34.9% vs 36.0% YoY; adjusted gross margin 35.5% vs 36.8%
- North America strongest: sales $2,738M, up 0.9%; International Personal Care weakest, sales $1,396M, down 2.8%
- Operating cash flow $2.4B nine-month, up from $1.8B; capital spending $1.0B vs $741M
- China diaper disruption remains a near-term headwind; incremental Middle East input costs estimated at approximately $250 for the year
AI summary of the KMB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 reports Kimberly-Clark’s results for the quarter ended September 30, 2026
- Investors should review the earnings release for revenue, profitability, guidance and operating drivers
Item EX-99.1: Item EX-99.1
- Q3 net sales $4.1B, down 0.4%, with organic sales down 1.3% amid China disruption and North American inventory headwinds
- Adjusted EPS from continuing operations $1.70, up 17.2%, helped by lower interest expense and adjusted tax rate
Item 2.03: Creation of a Direct Financial Obligation
- Financial obligation arises from the material agreement described in Item 1.01
- Investors must review Item 1.01 for borrowing amount, terms, maturity and purpose
Item 1.01: Entry into a Material Definitive Agreement
- KMB assumed $7.0B of Kenvue unsecured senior notes across maturities from 2028 through 2063
- Exchange retired $6.376B of Kenvue notes, leaving only $623.961M outstanding as Kenvue obligations
Item 3.03: Material Modification to Rights of Security Holders
- Rights modification tied to Kenvue notes assumption and exchange offers
- Investors should review Item 1.01 for affected securities, consent terms and potential ownership implications
Item 8.01: Other Events
- Final results announced for exchange offers and consent solicitations
- Investor impact depends on tender participation and approved consent outcomes
Item EX-99.1: Item EX-99.1
- Exchange offers attracted $6.376 billion of Kenvue notes, representing 90.8% of $7.0 billion outstanding
- Kimberly-Clark expected to issue up to $7.0 billion of matching-rate, unsecured senior notes, increasing consolidated debt obligations
Item 2.01: Completion of Acquisition or Disposition of Assets
- K-C completed its acquisition of Kenvue, adding Kenvue’s consumer-health business to Kimberly-Clark’s portfolio
- Kenvue shareholders received 0.14625 K-C shares plus $3.50 cash per share
Item 2.05: Costs Associated with Exit or Disposal Activities
- Kenvue Integration Program targets operating profit synergies by 2030, with actions underway through December 31, 2029
- Approximately $3.1 billion pre-tax charges, including $2.5 billion cash and $0.6 billion non-cash
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Three former Kenvue directors joined K-C’s board, with planned shareholder nomination at the 2027 annual meeting
- Board turnover created vacancies for the Kenvue appointees, with no departures attributed to company disagreements
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Amended bylaws effective November 2, 2026, upon completion of the Mergers
- Tighter advance-notice and disclosure rules for stockholder proposals and director nominations
Item 7.01: Regulation FD Disclosure
- K-C announced completion of the Mergers on November 2, 2026, marking a major corporate transaction milestone
- Integration of Kenvue now becomes the key execution focus, with potential synergies and cost savings dependent on successful integration
Item EX-99.1: Item EX-99.1
- Kenvue acquisition closed November 2, 2026, transforming KMB into a global consumer health and wellness platform
- Kenvue holders received $3.50 cash plus 0.14625 KMB shares per share, creating cash funding needs and shareholder dilution
AI summaries of KMB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KMB
Don't miss the next KMB filing
- Alerts as it files. A push when KMB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KMB, by share count.
- Ask anything. An AI agent that reads every KMB filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MERLO LARRY J | A | Nov 2, 2026 | 300 | - |
| CULVER JOHN | A | Nov 2, 2026 | 144 | - |
| ALLISON RICHARD E JR | A | Nov 2, 2026 | 300 | - |
| Perry Kirk | A | Nov 2, 2026 | 300 | - |
| Mahlan Deirdre | A | Nov 2, 2026 | 39 | - |
| Hsu Michael D. | A | Nov 2, 2026 | 10 | - |
| CULVER JOHN | A | Nov 2, 2026 | 28 | - |
| Carmichael John Patrick | M | Oct 31, 2026 | 2,196 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $20.1B | $16.4B |
| Gross Profit | $7.0B | $7.2B | $5.9B |
| Operating Income | - | $3.2B | $2.4B |
| Net Income | $1.8B | $2.5B | $2.0B |
| Gross Margin | - | 35.8% | 36.0% |
| Op. Margin | - | 16.0% | 14.3% |
| Net Margin | - | 12.7% | 12.3% |
| Balance Sheet | |||
| Total Assets | $17.3B | $16.5B | $17.1B |
| Equity | - | $840.0M | $1.5B |
| ROE | - | 303.0% | 134.6% |
| Per Share | |||
| EPS | $5.21 | $7.55 | $6.07 |
| Cash Flow | |||
| Operating CF | - | $3.2B | $2.8B |
Source: XBRL data in Kimberly-Clark (KMB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate KMB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 51 | $14.68B |
| Q2 2026 | 52 | $17.75B |
| Q1 2026 | 51 | $14.36B |
| Q4 2025 | 51 | $14.50B |
| Q3 2025 | 54 | $17.70B |
| Q2 2025 | 53 | $17.61B |
| Q1 2025 | 52 | $13.57B |
| Q4 2024 | 48 | $10.66B |
- Renaissance Technologies LLC+911.3K (+61%)
- JPMorgan Chase & Co+813.9K (+20%)
- Morgan Stanley+696.8K (+10%)
- Ameriprise Financial+640.2K (+95%)
- Bank of America Corp+560.7K (+8%)
- Citadel Advisors LLC−505.5K (-65%)
- Goldman Sachs Group−467.7K (-13%)
- T. Rowe Price Group−388.0K (-15%)
- State Street Corp−384.2K (-2%)
- Northern Trust−264.1K (-7%)
- Millennium Management+15.4K
- StoneX Group Inc.+3.0K
- Marex Group plc+2.7K
- FMR LLC (Fidelity)−13.13M
- AlTi Global, Inc.−55.7K
- Equitable Holdings Inc−4.6K
- PARK NATIONAL CORP /OH/−2.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 412 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KMB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 4 | Nov 2, 2026 | - | - | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 8-K | Oct 20, 2026 | - | Analysis | - |
| 8-K | Oct 15, 2026 | - | Analysis | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | May 14, 2026 | - | Analysis | |
| SC 13G | May 12, 2026 | - | - |
Related Consumer Staples companies
- ACI · Albertsons Companies IncRetail-Grocery Stores
- MO · AltriaCigarettes
- ANDE · Andersons, Inc.Wholesale-Farm Product Raw Materials
- BUD · Anheuser-Busch InBev SA/NVMalt Beverages
- ADM · Archer Daniels MidlandFats & Oils
- ARKO · ARKO Corp.Retail-Convenience Stores
- BGS · B&G Foods, Inc.Food and Kindred Products
- BYND · BEYOND MEAT, INC.Food and Kindred Products
KMB SEC filings: frequently asked questions
Which institutions hold KMB stock?
As of September 30, 2026, the largest Kimberly-Clark (KMB) holders among the 13F filers tracked by SignalX were BlackRock ($3.1 billion), Vanguard Capital Management LLC ($2.1 billion), State Street Corp ($2.0 billion), Vanguard Portfolio Management LLC ($1.6 billion), Morgan Stanley ($736.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KMB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Kimberly-Clark (KMB) reported revenue of $16.4 billion (down 18.0% from FY2024) and net income of $2.0 billion. Diluted EPS was $6.07. The figures come from the XBRL data in the 10-K.
What are the main risks in KMB's latest 10-K?
In the 10-K filed February 12, 2026, Kimberly-Clark (KMB) flagged: Regulatory risk from tightening data privacy and cybersecurity laws worldwide, increasing compliance costs and potential liabilities related to breaches of consumer data. Geopolitical exposure in Russia and surrounding region due to war in Ukraine, with operation curtailed and assets at risk of impairment. (AI summary of the Risk Factors section.)
What did KMB report in its latest 8-K?
Kimberly-Clark (KMB) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Exhibit 99.1 reports Kimberly-Clark’s results for the quarter ended September 30, 2026.
What are the latest KMB SEC filings?
Kimberly-Clark (KMB) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 4, 2026.
What is KMB's SEC CIK number?
Kimberly-Clark (KMB)'s SEC Central Index Key (CIK) is 55785. EDGAR lists every KMB filing under that number.
Ask anything about KMB
The research agent reads KMB's filings, financials, insider trades and 13F holders, then answers with sources.